Product Description: huATN-658 (MNPR-101) is a humanized monoclonal antibody inhibitor targeting urokinase-type plasminogen activator receptor (uPAR). huATN-658 blocks the interaction between uPAR and integrins, inhibiting the proliferation, invasion and migration of tumor cells. huATN-658 is promising for research of breast cancer (especially triple-negative breast cancer)[1][2].
Applications: Cancer-Kinase/protease
References: [1]Mahmood N, et al. uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions. Bone Res. 2020 Apr 17;8:18./[2]Nair R, et al. Preclinical Evaluation of Anti-uPAR Antibody as a Radiolabeled PET Imaging Candidate in Solid Tumors[J]. 2024.
Research Area: Cancer
Target: Integrin